The Implied Analyst 12-Month Target For VTHR

The Vanguard Russell 3000 ETF (VTHR) exhibits an implied 10.72% upside to its $329.19 analyst target price from its current $297.33, calculated from the weighted average of its underlying holdings' 12-month forward analyst targets. This potential is notably influenced by specific constituents like Aeva Technologies (AEVA), Jefferson Capital (JCAP), and Sionna Therapeutics (SION), which show individual upside projections ranging from 33.33% to 48.94%. Investors are advised to critically assess the justification and potential optimism behind these analyst targets, as further research is suggested.

Analysis

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 3000 ETF (Symbol: VTHR), we found that the implied analyst target price for the ETF based upon its underlying holdings is $329.19 per unit. With VTHR trading at a recent price near $297.33 per unit, that means that analysts see 10.72% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of VTHR's underlying holdings with notable upside to their analyst target prices are Aeva Technologies Inc (Symbol: AEVA), Jefferson Capital Inc (Symbol: JCAP), and Sionna Therapeutics Inc (Symbol: SION). Although AEVA has traded at a recent price of $15.98/share, the average analyst target is 48.94% higher at $23.80/share. Similarly, JCAP has 33.56% upside from the recent share price of $17.97 if the average analyst target price of $24.00/share is reached, and analysts on average are expecting SION to reach a target price of $38.00/share, which is 33.33% above the recent price of $28.50. Below is a twelve month price history chart comparing the stock performance of AEVA, JCAP, and SION: Below is a summary table of the current analyst target prices discussed above: | Name | Symbol | Recent Price | Avg. Analyst 12-Mo. Target | % Upside to Target | |---|---|---|---|---| | Vanguard Russell 3000 ETF | VTHR | $297.33 | $329.19 | 10.72% | | Aeva Technologies Inc | AEVA | $15.98 | $23.80 | 48.94% | | Jefferson Capital Inc | JCAP | $17.97 | $24.00 | 33.56% | | Sionna Therapeutics Inc | SION | $28.50 | $38.00 | 33.33% | Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets » Also see: Preferreds of SAFE Dividend Stocks CCRN Price Target FSP Dividend Growth Rate The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The Vanguard Russell 3000 ETF (VTHR) exhibits an implied analyst 12-month forward target price of $329.19, suggesting a 10.72% upside from its recent trading price of $297.33. This projection is a weighted average derived from the individual analyst targets of its underlying holdings. The general sentiment surrounding these targets is moderately positive, reflecting an optimistic outlook. Key drivers for VTHR's potential upside include specific constituents such as Aeva Technologies Inc (AEVA), Jefferson Capital Inc (JCAP), and Sionna Therapeutics Inc (SION). AEVA shows the most significant individual upside at 48.94% to its $23.80 target, from a recent price of $15.98. JCAP and SION also present substantial potential, with 33.56% and 33.33% upside to their respective targets of $24.00 and $38.00. However, the analysis highlights a crucial caveat, questioning the justification and potential over-optimism of these analyst targets. It suggests that some targets might be relics of the past, not fully reflecting current company or industry developments. Therefore, further investor research is recommended to validate these forward-looking projections.

Key Decisions for Investors

• Investors should critically evaluate the underlying assumptions and recency of analyst target prices for VTHR and its key constituents, particularly AEVA, JCAP, and SION.